Akebia Therapeutics (AKBA) Total Non-Current Liabilities (2013 - 2026)

Akebia Therapeutics (AKBA) has reported Total Non-Current Liabilities for 14 consecutive years, with $334.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 20.14% year-over-year to $334.5 million; the TTM figure through Mar 2026 stood at $334.5 million (up 20.14% YoY), while the FY2025 annual figure was $341.0 million, up 28.83% from the prior year.
• Total Non-Current Liabilities retreated to $334.5 million in Q1 2026 per AKBA's latest filing, from $341.0 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $436.1 million in Q1 2022 and bottomed at $247.8 million in Q1 2024.
• Historically, Total Non-Current Liabilities has averaged $308.5 million across 5 years, with a median of $283.3 million in 2023.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities tumbled 35.04% — and 2025, when it advanced 28.83%.
• Akebia Therapeutics' Total Non-Current Liabilities stood at $350.1 million in 2022, then decreased by 22.22% to $272.3 million in 2023, then declined by 2.79% to $264.7 million in 2024, then rose by 28.83% to $341.0 million in 2025, then slipped by 1.91% to $334.5 million in 2026.
• Business Quant data shows AKBA's Total Non-Current Liabilities at $334.5 million in Q1 2026, $341.0 million in Q4 2025, and $317.6 million in Q3 2025.